Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Epidemiology / Evaluating interventions

The randomised controlled trial

14 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Describe the essential features of a randomised controlled trial and why each protects against bias

  • Distinguish randomisation, allocation concealment and blinding

  • Describe the phases of clinical development and the CONSORT flow

The randomised controlled trial (RCT) is the benchmark for judging an intervention. Participants are allocated by chance to the intervention or a comparison (placebo, standard care), then followed for the outcome. Because chance decides allocation, groups are alike on all characteristics, measured and unmeasured, apart from the intervention, so differences in outcome can be attributed to it.

1,000Assessed for eligibility800Randomised400Allocated: intervention400 (all)Followed up and analysed (ITT)
A CONSORT-style flow: every stage is counted, and everyone randomised is analysed as allocated.

The ingredients of a good trial

FeaturePurposeNotes
Clear question (PICO)Population, Intervention, Comparator, OutcomeOne primary outcome
Eligibility criteriaDefine who is studiedTrade-off between internal validity and generalisability
RandomisationCreates comparable groupsComputer-generated sequence; blocks and stratification balance size and key factors
Allocation concealmentPrevents recruiters from foreseeing the next assignmentCentral telephone/web system, sealed opaque envelopes. Different from blinding.
Blinding (masking)Prevents knowledge of allocation changing behaviour or assessmentSingle, double, triple; placebo or sham
Sample sizePower to detect the minimal important effectChapter 9 of biostatistics
Follow-up and ITT analysisPreserve randomisationChapter 10 of biostatistics
Registration and protocolPrevent selective reportingClinicalTrials.gov, PACTR, ISRCTN
Ethics approval and consentProtect participantsDeclaration of Helsinki, ICH-GCP, national ethics committees (in Uganda: a REC plus the UNCST registration)

Randomisation, concealment and blinding are three different things

Randomisation generates an unpredictable sequence. Allocation concealment keeps that sequence hidden until the participant is irreversibly enrolled; without it, a recruiter can steer sicker patients away from one arm and ruin the randomisation. Blinding conceals the assigned arm after allocation from participants, clinicians and outcome assessors. Concealment is always possible; blinding sometimes is not (surgery vs medicine, behavioural interventions).

Types of randomisation

  • Simple: like tossing a coin; fine for large trials but can leave unequal groups in small ones.
  • Block: randomise within blocks of, say, 4 or 6, so group sizes stay balanced throughout.
  • Stratified: separate sequences within strata of key prognostic factors (site, sex).
  • Minimisation: a deterministic method that balances several factors in small trials.

Phases of clinical development

PhaseTypical sizeMain aim
I20 to 100 (often healthy volunteers)Safety, dose, pharmacokinetics
II100 to 300Early efficacy and side effects; dose selection
III300 to thousandsConfirm efficacy and safety against standard care; basis for licensing
IV (post-marketing)ThousandsLong-term and rare safety; real-world effectiveness

Strengths and limitations of RCTs

Strengths: control of confounding, a causal interpretation, a framework for blinded assessment. Limitations: cost; ethical limits (cannot randomise harmful exposures); strict eligibility limits generalisation; short follow-up; hard to blind complex interventions; unsuitable for rare outcomes unless very large.

Concealment failure

In a trial of a new antimalarial regimen, envelopes were not opaque; recruiters held them up to the light and the clinician could tell which treatment the next child would get. Severely ill children tended to be steered toward the newer drug. The treatment groups differed in severity at baseline, and the apparent benefit of the new drug was inflated. Meta-epidemiological studies find that trials with inadequate or unclear concealment tend to exaggerate treatment effects.

Common weaknesses to look for

Unclear randomisation method; no concealment; outcome assessors not blinded for a subjective outcome; large or unbalanced losses; analysis of 'per protocol' only; switching of the primary outcome after the results; no trial registration; spin in the abstract.

Appraisal shortcut

Use the Cochrane RoB 2 domains: randomisation process, deviations from the intended intervention, missing outcome data, measurement of the outcome and selection of the reported result.

Summary

  • Random allocation creates comparable groups and supports causal inference.

  • Randomisation, allocation concealment and blinding are distinct protections.

  • Phases I to IV move from safety to confirmation to post-marketing surveillance.

  • Register trials, obtain ethical approval, pre-specify the primary outcome and analyse by intention to treat.

  • RCTs have limits: cost, ethics, generalisability and feasibility.

Check your understanding

Question 1
1

Allocation concealment prevents:

Question 2
2

Which trial phase compares efficacy and safety with standard care in hundreds to thousands of patients?

Question 3
3

The main advantage of randomisation is that it balances:

Question 4
4

Blocked randomisation helps to:

Question 5
5

An open-label surgical trial cannot blind surgeons. Which safeguard is still possible?

Question 6
6

Registration of a trial protocol primarily prevents:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

Evaluating screening and diagnostic programmes in practiceCluster, stepped-wedge and pragmatic trials